Mind Medicine MindMed (MNMD)
(Delayed Data from NSDQ)
$5.92 USD
+0.11 (1.81%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $5.93 +0.02 (0.25%) 5:58 PM ET
2-Buy of 5 2
D Value C Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Mind Medicine (MindMed) Inc. [MNMD]
Reports for Purchase
Showing records 1 - 20 ( 83 total )
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Lead Program Advancing to Phase 3 in Anxiety in 2H24; Expanding Pipeline in Depression in 1H25; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways From Biotech Breakthroughs Event: A Long Position in Short-Acting Psychedelics
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
2Q: On Track For Initiating Phase 3 In The Second Half
Provider: Roth Capital Partners, Inc.
Analyst: WITTES J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Neuro Perspectives Conference Takeaways: Investable Opportunities in Mental Health and Neurological Disorders
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Transfer of Coverage Maintaining Buy and $36 PT
Provider: Roth Capital Partners, Inc.
Analyst: WITTES J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Lykos Lessons: Functional Unblinding, Treatment Durability, Role of Psychotherapy, Safety, and a Proposed REMS
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
BioConnect Conference Takeaways: Psychedelic MM120 Emerging as Leading Anxiety Treatment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Multiple Conference Presentations Reinforce Potential of MM120 in Anxiety
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaway From Biotech Breakthroughs Oncology Event: The Rise of PRAME-Targeted Therapies
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaway From Biotech Breakthroughs Psychiatry Event
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Longer-Term Phase 2 Data Increases Confidence in Anxiety Program; Expect Phase 3 Program Start in 2H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Durable MM120 Delivers 12-Week Data Solid As 4-Week Data in GAD, Gets BTD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Expect Lead Psychedelic MM-120 to Advance to Phase 3 in Anxiety in 2H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
4Q23: Expecting Substantial MM120 Progress Over 2024, Funded Into 2026
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
MM-120 Progressing Toward Phase 3 Development in Anxiety Following Robust Phase 2b Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Topline Phase 2b Data Demonstrate Clear MM-120 Benefit in Treating GAD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J